Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
Tango Therapeutics will present updated Phase 1/2 data for vopimetostat combined with daraxonrasib or zoldonrasib in MTAP-deleted RAS-mutant metastatic PDAC and NSCLC at the ESMO Congress 2026 (Oct 23-27, Madrid). The poster (abstract #3149P) will be presented by Alexander I. Spira on October 25; abstracts publish October 19, and the company will host a PDAC-focused investor webcast on October 23 at 7:30 am ET.
Key figures
- Drug Name
- vopimetostat
- Phase Of Trial
- Phase 1/2
- Webcast
- PDAC-focused investor webcast October 23, 2026, 7:30 am ET
- Data cutoff
- April 3, 2026
- Poster date
- October 25, 2026
- Combinations
- daraxonrasib or zoldonrasib
- Abstract number
- 3149P
- Trial population
- MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic PDAC and NSCLC
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.